 Connection
Paul Drew to Encephalomyelitis, Autoimmune, Experimental
This is a "connection" page, showing publications Paul Drew has written about Encephalomyelitis, Autoimmune, Experimental.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.691 |
|
|
|
-
Xu J, Wagoner G, Douglas JC, Drew PD. ?-Lapachone ameliorization of experimental autoimmune encephalomyelitis. J Neuroimmunol. 2013 Jan 15; 254(1-2):46-54.
Score: 0.408
-
Xie L, Chen J, McMickle A, Awar N, Nady S, Sredni B, Drew PD, Yu S. The immunomodulator AS101 suppresses production of inflammatory cytokines and ameliorates the pathogenesis of experimental autoimmune encephalomyelitis. J Neuroimmunol. 2014 Aug 15; 273(1-2):31-41.
Score: 0.115
-
Lovett-Racke AE, Hussain RZ, Northrop S, Choy J, Rocchini A, Matthes L, Chavis JA, Diab A, Drew PD, Racke MK. Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J Immunol. 2004 May 01; 172(9):5790-8.
Score: 0.057
-
Diab A, Hussain RZ, Lovett-Racke AE, Chavis JA, Drew PD, Racke MK. Ligands for the peroxisome proliferator-activated receptor-gamma and the retinoid X receptor exert additive anti-inflammatory effects on experimental autoimmune encephalomyelitis. J Neuroimmunol. 2004 Mar; 148(1-2):116-26.
Score: 0.056
-
Drew PD, Chavis JA, Bhatt R. Sex steroid regulation of microglial cell activation: relevance to multiple sclerosis. Ann N Y Acad Sci. 2003 Dec; 1007:329-34.
Score: 0.055
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|